{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urinary-tract-infection-children/prescribing-information/cefalexin/","result":{"pageContext":{"chapter":{"id":"f0eecb36-6697-52c3-ba61-43722573d661","slug":"cefalexin","fullItemName":"Cefalexin","depth":2,"htmlHeader":"<!-- begin field 2c94488c-4806-4951-bdd7-fa22fbcfb689 --><h2>Cefalexin</h2><!-- end field 2c94488c-4806-4951-bdd7-fa22fbcfb689 -->","summary":"","htmlStringContent":"<!-- begin item a12d1fe1-ac21-48a7-9f86-6a211b5dc3cd --><!-- end item a12d1fe1-ac21-48a7-9f86-6a211b5dc3cd -->","topic":{"id":"991f627d-8926-57b4-aaf8-67af4fd5db9d","topicId":"510a3aa0-27ac-462a-a52b-fe6491d08ab0","topicName":"Urinary tract infection - children","slug":"urinary-tract-infection-children","lastRevised":"Last revised in February 2019","chapters":[{"id":"d1ecfd05-b7d6-5f26-958b-08cbc3d78492","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5867e1c1-3817-541e-8b04-bef811c2f6c4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"79d4f794-da69-53db-a658-5ce7c959f692","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2f77533f-9993-5dbe-aec4-d0ee486a2559","slug":"changes","fullItemName":"Changes"},{"id":"79054143-84a5-50b1-8bcd-34d7ea4ff7da","slug":"update","fullItemName":"Update"}]},{"id":"26055421-3310-5e60-9152-68faccc1b450","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2e0770ba-47ca-5e33-8ed4-cc1f3f27b080","slug":"goals","fullItemName":"Goals"},{"id":"9b22c988-34f6-555d-9dc3-8ab3bb093e3a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fe1b7a61-e520-56e2-be30-8608881cdb7f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2b6a45d0-fdcd-5821-864d-63a74db81d6a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6f051e1-15a3-55a3-be65-2a623b2dae1c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8b4bab45-57e8-59b8-bd66-9036dc2fc571","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"dd9ffb6c-bd87-54d5-8c87-1e080e01ea4b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"1136e250-9882-5b2e-a75c-91e52993494f","slug":"definition","fullItemName":"Definition"},{"id":"45b0687c-19a3-5dc0-a5aa-e56c1e8d1061","slug":"causal-organisms","fullItemName":"Causal organisms"},{"id":"003daae9-bb06-5297-8ac5-cabcf10e7968","slug":"prevalence","fullItemName":"Prevalence"},{"id":"750a5b3e-7655-5653-bd66-cbf33a4daffe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"2d85acf8-d02b-5815-bb49-4c5f17b8678f","slug":"prognosis","fullItemName":"Prognosis"},{"id":"9f9d006d-bcda-5469-81d7-d2c3123c99d4","slug":"complications","fullItemName":"Complications"}]},{"id":"0bd6000e-bd4c-5f90-a711-bd23da73865d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8f91b779-7c82-5647-b2f7-d8c90726d303","slug":"suspecting-a-urinary-tract-infection","fullItemName":"Suspecting a urinary tract infection"},{"id":"5e82d0e6-4bfb-58c7-955f-7d2bc44d7ff6","slug":"diagnosing-a-urinary-tract-infection","fullItemName":"Diagnosing a urinary tract infection"},{"id":"57282b06-7213-5787-8603-4673c4ead4c4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d3a08393-35d5-53dc-935a-d5e32abee30b","fullItemName":"Management","slug":"management","subChapters":[{"id":"732454b5-6086-54ad-8fe0-68d4d8c9b5f8","slug":"uti-in-children","fullItemName":"Scenario: UTI in children"},{"id":"47d251fa-94da-5df5-889b-aec47b266935","slug":"recurrent-uti-in-children","fullItemName":"Scenario: Recurrent UTI in children"}]},{"id":"fcc5959a-b3b9-5135-9a34-0567f5ec597e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"49e814b6-1bc7-5c87-91e7-ea6edc49413f","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"178d0dc1-f68e-5c02-8ab6-590182cdb89b","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin"},{"id":"f0eecb36-6697-52c3-ba61-43722573d661","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"32a374c4-43e1-56a3-bc3a-3750191e085c","slug":"amoxicillin","fullItemName":"Amoxicillin"}]},{"id":"8b665f09-70b4-5fb0-a6c8-77c4766fc268","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1d405e7c-5e75-5615-8deb-94bb5f1d64cb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"82284d2f-4c04-573e-861c-5f030553a063","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"27e92d92-08e0-5fd8-aa0b-a5d456171c04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3afd108c-e35b-5034-9573-81cf33f52df5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ce068350-baea-5cb3-9040-ab2a90e020f8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e6c46138-9934-5c77-9727-4d36f784738d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"46eac86e-96b0-524a-ac9a-887b17be1e1c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fcc5959a-b3b9-5135-9a34-0567f5ec597e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"bdedb26a-5771-5c49-932c-721e112605fd","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 6f619260-0161-4f3c-9621-a82a01269068 --><h3>Contraindications and cautions</h3><!-- end field 6f619260-0161-4f3c-9621-a82a01269068 -->","summary":"","htmlStringContent":"<!-- begin item efff1511-7968-494b-9976-a82a01268c40 --><!-- begin field 9c1a5a39-8cbf-43d2-83af-a82a01269068 --><ul><li><strong>Do not prescribe cefalexin in people with: </strong><ul><li>A known allergy to the cephalosporin group of antibiotics or a history of immediate hypersensitivity to penicillin and other beta-lactams.</li></ul></li><li><strong>Prescribe cefalexin with caution in people with:</strong><ul><li>Sensitivity to penicillin and other beta lactams. About 0.5–6.5% of penicillin-sensitive people will also be allergic to cephalosporins.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">BNF 76, 2018</a>]</p><!-- end field 9c1a5a39-8cbf-43d2-83af-a82a01269068 --><!-- end item efff1511-7968-494b-9976-a82a01268c40 -->","subChapters":[]},{"id":"f61e6764-d5d5-582d-bd8c-96b59ab5c623","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field c1215176-a338-4dea-a363-a82a0126ba19 --><h3>Adverse effects</h3><!-- end field c1215176-a338-4dea-a363-a82a0126ba19 -->","summary":"","htmlStringContent":"<!-- begin item 9d0fe830-6e2e-49a0-884b-a82a0126b608 --><!-- begin field 0b2fcf0c-6aa9-44bc-8ff4-a82a0126ba19 --><ul><li><strong>Gastrointestinal </strong>— diarrhoea, abdominal pain, nausea, vomiting (common).</li><li><strong>Nervous system</strong> — headache, dizziness (common).</li><li><strong>Psychiatric </strong>— hallucinations, confusion, agitation (frequency unknown).</li><li><strong>Skin</strong> — rash, urticaria, pruritus.<ul><li><strong>Rarely:</strong> erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis (exanthematic necrolysis)</li></ul></li><li><strong>Other adverse effects include:</strong> <ul><li>Anaphylaxis.</li><li>Arthralgia and myalgia.</li><li>Eosinophilia, neutropenia, thrombocytopenia, haemolytic anaemia. </li><li>Genital and anal pruritus.</li><li>Hepatitis, cholestatic jaundice.</li><li>Interstitial nephritis (rarely).</li><li>Pseudomembranous colitis (for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">BNF 76, 2018</a>]</p><!-- end field 0b2fcf0c-6aa9-44bc-8ff4-a82a0126ba19 --><!-- end item 9d0fe830-6e2e-49a0-884b-a82a0126b608 -->","subChapters":[]},{"id":"a7ab3b25-29eb-54da-820e-4053dd7d5c39","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6a33258b-98fe-4ec1-a80c-a82a0126f3aa --><h3>Drug interactions</h3><!-- end field 6a33258b-98fe-4ec1-a80c-a82a0126f3aa -->","summary":"","htmlStringContent":"<!-- begin item 95a09683-28a0-4968-82cb-a82a0126eea0 --><!-- begin field eb254ef4-5e79-4a35-a3b8-a82a0126f3aa --><ul><li><strong>Aminoglycosides </strong>(for example, gentamicin) — possible increased risk of nephrotoxicity. Routine renal monitoring for the aminoglycoside is usually adequate.</li><li><strong>Oral anticoagulants </strong>(warfarin and phenindione) — cefalexin may enhance the anticoagulant effect. Monitor the international normalized ratio (INR) closely during concomitant use. </li><li><strong>Probenecid</strong> — renal excretion of cefalexin is inhibited. However, no dose adjustment is normally required.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">BNF 76, 2018</a>]</p><!-- end field eb254ef4-5e79-4a35-a3b8-a82a0126f3aa --><!-- end item 95a09683-28a0-4968-82cb-a82a0126eea0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}